Drug Profile
CS 917
Alternative Names: CS-917; MB 6322; MB06322Latest Information Update: 23 Jan 2008
Price :
$50
*
At a glance
- Originator Metabasis Therapeutics
- Developer Daiichi Sankyo Inc; Metabasis Therapeutics
- Class Amino acids; Antihyperglycaemics; Organophosphorus compounds; Small molecules
- Mechanism of Action Fructose bisphosphatase inhibitors; Gluconeogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 29 Jun 2007 Data presented at the 67th Scientific Sessions of the American Diabetes Association (ADA-2007) added to the Diabetes pharmacodynamics section
- 26 Jun 2007 Daiichi Sankyo completes a phase IIb trial in Diabetes in the US
- 01 Feb 2007 Daiichi Sankyo completes enrolment in its phase IIb trial for Type-2 diabetes in USA